Health authorities continue to underscore the importance of vaccination as a key intervention against mpox (formerly known as monkeypox), a viral disease that remains a public health concern globally, particularly among at-risk populations. The primary vaccine used during recent outbreaks is the Modified Vaccinia Ankara (MVA) vaccine, marketed as JYNNEOS in the United States, Imvanex in Europe, and Imvamune in Canada. JYNNEOS, a non-replicating vaccine, has been the cornerstone for both pre-exposure and post-exposure prophylaxis due to its safety profile and effectiveness in preventing severe disease.
Vaccination Recommendations and Effectiveness
JYNNEOS vaccine is administered as a two-dose series, 28 days apart, and studies indicate that completing both doses offers optimal protection against mpox. The Centers for Disease Control and Prevention (CDC) reports that vaccination with two doses can reduce the risk of contracting mpox by approximately 86-89%. While a single dose provides some protection, the full two-dose schedule is necessary to achieve the highest level of immunity.
The vaccine is recommended for adults aged 18 years and older who are at increased risk of mpox exposure, including men who have sex with men, transgender and nonbinary individuals with recent high-risk exposures, healthcare workers with potential occupational exposure, and those who have been in close contact with confirmed mpox cases. Vaccination can be given either before exposure to reduce infection risk or after exposure to lessen the likelihood of developing symptoms or severe disease, ideally within four days of contact but up to 14 days if no symptoms have appeared.
Clinical Outcomes and Safety Profile
While breakthrough infections after vaccination may occur, evidence shows these tend to manifest with milder symptoms compared to infections in unvaccinated individuals. Importantly, no booster doses beyond the two-dose primary series are currently recommended, and individuals who have recovered from mpox are not advised to receive the vaccine at this time due to the rarity of reinfection and generally milder course if reinfection occurs.
JYNNEOS is favored over older vaccines such as ACAM2000, a live replicating smallpox vaccine still available but generally reserved for situations where safer alternatives are not accessible, because of the lower risk of side effects and no risk of vaccine virus transmission. The vaccine is usually administered in the upper arm, a site change that has resulted in fewer local skin reactions and improved tolerability.
Treatment and Protection Measures
Currently, there is no antiviral medication formally approved specifically for mpox, although antivirals like tecovirimat (TPOXX) are used under expanded access or emergency authorization protocols, especially for severe illness or immunocompromised patients. Management primarily focuses on supportive care, including symptom relief, hydration, and prevention of secondary infections.
The World Health Organization (WHO) emphasizes prioritizing vaccination for individuals at highest risk — such as immunocompromised persons, young children, pregnant women, and those in close contact with confirmed cases — and does not currently recommend mass vaccination of the general population. Healthcare providers advise maintaining vigilance for symptoms, reducing close physical contact with infected individuals, and seeking vaccination promptly if at risk.
Public Health Significance
This vaccination strategy is vital to controlling mpox outbreaks, reducing hospitalizations, and preventing fatalities, especially among vulnerable populations. Early vaccine administration post-exposure is a critical window to curb transmission and severe disease. The approach also reflects balanced use of limited vaccine supplies to protect those most at risk, optimize public health outcomes, and minimize unnecessary vaccination in low-risk groups.
As mpox remains a dynamic global health issue, ongoing surveillance, vaccine accessibility, and public education are essential components to mitigate the disease burden effectively. Efforts to evaluate and improve therapeutics in clinical trials continue to complement vaccination as part of comprehensive mpox management.
For detailed guidance on vaccination and mpox prevention measures, consult resources such as the World Health Organization on mpox and the U.S. Centers for Disease Control and Prevention.
Read more on Globally Pulse Health for updates on infectious diseases and vaccine developments.
